Proactive Investors - Run By Investors For Investors

ReNeuron Group agrees £80mln cell therapy licensing deal for China

ReNeuron Group PLC's (LON:RENE) Michael Hunt talks Proactive London's Andrew Scott through a deal they've signed which is potentially worth up to £80mln in success-based payments with an arm of one of China's leading drug companies.

Fosun Pharma is licensing the rights to the company’s CTX and hRPC cell therapy programmes in the People’s Republic for an initial £6mln.

 
Meet Rockfire Resources PLC, Touchstone Exploration Inc, Mkango Resources Ltd and Salt Lake Potash Ltd at our event, London , 20 June 2019. Register here »
View full RENE profile View Profile

ReNeuron Group PLC Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use